Universal Technical Institute Inc is an educational institution... Show more
Universal Technical Institute shares have experienced notable volatility through mid-2026. The stock climbed from roughly $38 at the start of June to a 52-week high of $51.34 by early July, fueled by bullish analyst revisions, strong enrollment trends, and growing investor interest in workforce education names tied to AI-driven labor market shifts. That rally reversed sharply in mid-July, with shares falling to the $35–$36 range before stabilizing near $40 in late July. The broader narrative pits the company's tangible growth story — accelerating campus openings, rising student counts, and consistent revenue expansion — against valuation concerns, significant insider selling, and the stock's elevated multiples relative to historical averages.
Universal Technical Institute is a leading workforce solutions provider offering post-secondary education across two divisions: the flagship UTI segment, which trains students for careers as automotive, diesel, collision repair, motorcycle, marine, and welding technicians, and the Concorde Career Colleges segment, which focuses on healthcare education including nursing, dental, and patient care programs. With a national campus network and select Canadian locations, UTI delivers diploma and certificate programs typically ranging from 36 to 74 weeks. The company collaborates closely with original equipment manufacturers to align its curriculum with industry needs. UTI competes alongside peers such as LINC (Lincoln Educational Services) in the skilled-trades education market, and its dual-segment model positions it to capture demand across both the transportation and healthcare education sectors.
Several factors have shaped investor sentiment over the past 30 days. On June 29, Truist Financial raised its price target on UTI from $40 to $47 while maintaining a Buy rating, citing positive takeaways from an investor call with COO Todd Hitchcock. The analyst highlighted how AI-driven displacement of white-collar workers could structurally benefit trade schools, as demand for skilled manual labor remains resilient. That bullish call contributed to the stock's early-July surge past $50.
Operationally, the company's new San Antonio campus — its first dedicated skilled-trades facility — opened in March 2026 with student starts running approximately 60% above plan, validating management's expansion playbook. The UTI-Atlanta campus began student recruitment ahead of its planned mid-2026 launch, and lease agreements were signed for new Concorde campuses in Atlanta, Houston, and Glendale, Arizona, targeting 2027 openings.
However, a significant volume of insider selling has weighed on sentiment. Over the trailing 90 days, insiders sold approximately 3.12 million shares worth nearly $129 million. CEO Jerome Alan Grant sold 94,500 shares at an average price of $41.40 in late June, while Director Linda J. Srere and CAO Christine Kline also reduced their holdings. No insider purchases were reported during this period. Meanwhile, institutional ownership remains robust at roughly 75.7%, with several funds — including Sei Investments and Coliseum Capital Management — increasing their positions in recent quarters.
The sharp correction in mid-July coincided with a broader re-evaluation of growth stocks trading at elevated multiples. UTI's trailing P/E ratio of approximately 49–53x sits well above its five-year median of roughly 35x, prompting valuation-focused analysts and data services to flag the stock as potentially overvalued relative to near-term earnings power. Weiss Ratings upgraded UTI to a Hold (C+) rating in late July, reflecting a more cautious near-term view.
For investors seeking data-driven approaches to navigate stocks like Universal Technical Institute, Tickeron's Trending AI Robots page provides a curated view of top-performing AI trading bots. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers across varying strategies, timeframes, and performance benchmarks. Only the most relevant and consistently high-performing bots appear in this featured section, allowing traders to evaluate algorithmic strategies tailored to current market conditions. Whether focused on short-term momentum, swing trading, or longer-term thematic positioning, the Trending AI Robots page serves as a resource for discovering AI-driven trading tools actively generating signals in real time.
The upcoming Q3 FY2026 earnings report, expected on August 5, 2026, serves as the nearest catalyst. Analysts forecast earnings of approximately $0.01 per share and revenue near $220.4 million. Investors will closely monitor new student start figures, average full-time active student counts, and any updates to the full-year guidance, which currently calls for revenue of $905–$915 million and diluted EPS of $0.71–$0.80.
Beyond the quarterly print, the successful launch and ramp-up of the UTI-Atlanta campus, progress on Concorde campus development, and the trajectory of strategic growth spending will be critical signposts. The company's long-term North Star targets — $1.2 billion in revenue and adjusted EBITDA approaching $220 million by fiscal 2029 — depend on disciplined execution across multiple new campus openings. Broader macroeconomic factors, including labor market trends, federal education policy, and the pace of AI-driven workforce disruption, also remain influential to the skilled-trades education thesis. Insider trading patterns and institutional positioning will likely continue shaping sentiment in the months ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .
UTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on August 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTI as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for UTI turned negative on August 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
UTI moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for UTI crossed bearishly below the 50-day moving average on July 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for UTI entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. UTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.103) is normal, around the industry mean (2.292). P/E Ratio (42.033) is within average values for comparable stocks, (28.901). UTI's Projected Growth (PEG Ratio) (2.279) is slightly higher than the industry average of (1.221). Dividend Yield (0.000) settles around the average of (0.053) among similar stocks. P/S Ratio (1.621) is also within normal values, averaging (1.536).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of technical education
Industry OtherConsumerSpecialties